Orexin/Hypocretin System in ME/CFS and Related Conditions
This section covers mechanistic studies on the orexin/hypocretin system relevant to ME/CFS: inflammation-induced suppression of orexin neurons, post-infectious and post-COVID orexin dysfunction, sleep architecture instability, narcolepsy-overlap mechanisms, and emerging orexin-targeted therapeutics.
1 Sakurai et al. 1998 — Discovery of Orexins and Orexin Receptors
Full Citation:: Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(5):573–585. DOI:: 10.1016/S0092-8674(02)09256-5 PMID:: 9527442 Study Design:: Foundational discovery (reverse pharmacology, animal)
Key Findings: Identified orexin-A (33 aa) and orexin-B (28 aa) as novel hypothalamic neuropeptides activating two orphan GPCRs: OX1R (selective for orexin-A) and OX2R (non-selective). Prepro-orexin mRNA localizes to the lateral and posterior hypothalamus. Central administration stimulates food intake; fasting up-regulates prepro-orexin mRNA. Established that the orexin system is a lateral hypothalamic integrator of energy status, arousal, and autonomic output.
Relevance to ME/CFS: Foundational reference for all orexin biology. Any ME/CFS model proposing hypothalamic orexinergic dysfunction traces back to this discovery paper.
Certainty Assessment:
- Quality: Very High (Cell, landmark molecular discovery)
- Direct ME/CFS evidence: None (foundational mechanistic reference)
- Limitations: Original scope was feeding behavior; sleep/arousal roles established in follow-up work
2 Grossberg et al. 2011 — Inflammation-Induced Lethargy via Orexin Suppression
Full Citation:: Grossberg AJ, Zhu X, Leinninger GM, Levasseur PR, Braun TP, Myers MG Jr, Marks DL. Inflammation-induced lethargy is mediated by suppression of orexin neuron activity. Journal of Neuroscience. 2011;31(31):11376–11386. DOI:: 10.1523/JNEUROSCI.2311-11.2011 PMID:: 21813697 Study Design:: Experimental animal study (rat/mouse), pharmacological rescue Sample Size:: 3–12 animals per group
Key Findings: During systemic LPS inflammation, orexin neuron activity in the perifornical hypothalamus is suppressed: CSF orexin-A levels decrease and dark-phase activation of Ox neurons is blocked. Central orexin-A replacement reverses inflammation-induced locomotor suppression. Orexin neurons themselves lack direct cytokine/LPS receptors; suppression is mediated indirectly via lateral hypothalamic neurotensin-expressing interneurons activated during inflammation. Prostaglandin and melanocortin pathways were not required.
Mechanism for ME/CFS: Establishes a specific neural circuit: cytokines (IL-1\(\beta\), TNF\(\alpha\)) to neurotensin neurons to orexin neuron suppression to lethargy. In ME/CFS with chronic low-grade neuroinflammation, this pathway would produce persistent orexinergic suppression even without acute infection.
Certainty Assessment:
- Quality: High (Journal of Neuroscience, mechanistic animal study)
- Direct ME/CFS evidence: None (animal mechanistic)
- Certainty: 0.65 (strong mechanism; translation pending)
- Limitations: Acute inflammation model; chronic low-grade ME/CFS neuroinflammation untested
3 Gaykema & Goehler 2009 — LPS Suppresses Orexin Neurons in Sickness Behavior
Full Citation:: Gaykema RPA, Goehler LE. Lipopolysaccharide challenge-induced suppression of Fos in hypothalamic orexin neurons: their potential role in sickness behavior. Brain, Behavior, and Immunity. 2009;23(7):926–930. DOI:: 10.1016/j.bbi.2009.03.005 PMID:: 19328847 Study Design:: Rat in vivo, Fos immunohistochemistry Sample Size:: n\(\\approx\) 6–8 per condition
Key Findings: LPS challenge markedly reduces Fos expression in lateral orexin neurons during exploratory behavior (47% to 25%) and dark-phase activity (42% to 9%). Histaminergic tuberomammillary neurons show parallel suppression (64% to 11%), indicating co-shutdown of the orexin–histamine arousal axis. Proposes orexin–histamine circuit suppression as the neural substrate of sickness-related inactivity and withdrawal.
Relevance to ME/CFS: Provides Fos evidence for context-dependent orexin suppression during peripheral immune challenge. In ME/CFS, persistent immune activation would chronically suppress this arousal circuit.
Certainty Assessment:
- Quality: High (BBI, well-controlled histochemistry)
- Certainty: 0.60
- Limitations: Acute LPS model; chronic immune activation not modeled
4 Weymann et al. 2014 — Orexin in Chemotherapy-Induced Fatigue
Full Citation:: Weymann KB, Wood LJ, Zhu X, Marks DL. A role for orexin in cytotoxic chemotherapy-induced fatigue. Brain, Behavior, and Immunity. 2014;37:84–94. DOI:: 10.1016/j.bbi.2013.11.003 PMID:: 24216337 Study Design:: Rodent experimental (mice/rats), pharmacological rescue Sample Size:: n=6–12 per group
Key Findings: CAF chemotherapy (cyclophosphamide/adriamycin/5-fluorouracil) induces hypothalamic neuroinflammation (IL-1R1, IL-6, TNF\(\alpha\), MCP-1 elevated). Orexin neuron activity suppressed (reduced nuclear cFos, decreased CSF orexin-A). Fatigue behaviors correlate with orexin suppression. Causal test: central orexin-A (1 \(\mu\)g) administration fully restores activity in CAF-treated rats, demonstrating that orexin depletion drives fatigue rather than merely accompanying it.
Relevance to ME/CFS: Provides causal evidence for the cytokine-to-hypothalamic-inflammation-to-orexin-suppression-to-fatigue chain. The pharmacological rescue is directly translatable to ME/CFS neuroimmune fatigue models.
Certainty Assessment:
- Quality: High (BBI, pharmacological rescue design)
- Certainty: 0.55 (strong mechanism; no human translation yet)
- Limitations: Acute chemotherapy model; preclinical only; no ME/CFS patients
5 Ito et al. 2023 — Orexin Deficiency and REM Sleep Instability
Full Citation:: Ito H, Fukatsu N, Rahaman SM, Mukai Y, Izawa S, Ono D, Kilduff TS, Yamanaka A. Deficiency of orexin signaling during sleep is involved in abnormal REM sleep architecture in narcolepsy. Proceedings of the National Academy of Sciences U.S.A. 2023;120(41):e2301951120. DOI:: 10.1073/pnas.2301951120 PMID:: 37796986 Study Design:: Mouse optogenetics + calcium imaging (causal) Sample Size:: Animal (multiple groups per experiment)
Key Findings: Orexin neurons are highly active during wakefulness, show synchronised bursting during NREM sleep, become silent before NREM-to-REM transitions, and a subpopulation active during REM suppresses subsequent REM sleep and cataplexy. When orexin signaling is absent (narcoleptic mice), this suppression mechanism fails, resulting in excessive REM intrusions and sleep fragmentation. Optogenetic inhibition confirms causality.
Relevance to ME/CFS: Mechanistic basis for how partial orexin deficiency produces sleep-wake instability: insufficient orexin during sleep leads to loss of REM gating and alpha intrusion into NREM, yielding unrefreshing sleep — a cardinal ME/CFS symptom.
Certainty Assessment:
- Quality: High (PNAS, optogenetic causal design)
- Certainty: 0.65 (strong mechanism; human translation needed)
- Limitations: Complete orexin-neuron-ablation model; partial deficiency (ME/CFS scenario) not directly tested
6 Rauf et al. 2025 — Narcolepsy Mechanisms and Orexin Agonist Therapeutics
Full Citation:: Rauf R, Asif S, AlSaafeen A, et al. Orexin deficiency in narcolepsy: molecular mechanisms, clinical phenotypes, and emerging therapeutic frontiers. Brain and Behavior. 2025;15(10):e70984. DOI:: 10.1002/brb3.70984 PMID:: 41076550 Study Design:: Narrative review Sample Size:: N/A (review)
Key Findings: Over 90% of NT1 patients have CSF orexin-A below 110 pg/mL and carry HLA-DQB1*06:02, confirming autoimmune destruction of up to 95% of hypothalamic orexin neurons. H1N1 influenza and Pandemrix vaccination trigger temporal NT1 clustering, establishing post-infectious immune-mediated orexin loss as a proven mechanism. Danavorexton (OX2R-selective agonist) improved Maintenance of Wakefulness Test by 11.1 points versus modafinil.
Relevance to ME/CFS: Post-infectious orexin loss mechanism (H1N1 to NT1) directly parallels ME/CFS viral triggers. ME/CFS may occupy an intermediate orexin deficiency zone (110–200 pg/mL), between narcolepsy (\(<\) 110) and healthy (\(>\) 200). OX2R agonists represent a therapeutic class relevant to any partial orexin deficiency state.
Certainty Assessment:
- Quality: Medium (Brain and Behavior; narrative review)
- Certainty: 0.60 for narcolepsy mechanisms; 0.35 for ME/CFS applicability
- Limitations: Narrative review; ME/CFS section absent; analogy not tested
7 Ruhrländer et al. 2025 — Orexin System and Autonomic Dysfunction in PASC
Full Citation:: Ruhrländer J, Syntila S, Schieffer E, Schieffer B. The orexin system and its impact on the autonomic nervous and cardiometabolic system in post-acute sequelae of COVID-19. Biomedicines. 2025;13(3):545. DOI:: 10.3390/biomedicines13030545 PMID:: 40149526 Study Design:: Narrative review Sample Size:: N/A (review)
Key Findings: Orexin dysregulation plausibly underlies PASC autonomic and cardiometabolic symptoms: orexin regulates baroreflex sensitivity, sympathetic tone, catecholamine release, electrolyte balance, and circadian rhythms. Disruption explains POTS, orthostatic hypotension, endothelial dysfunction, and insulin resistance. Most mechanistic evidence is animal-derived; human PASC-specific orexin measurements are lacking.
Relevance to ME/CFS: PASC and ME/CFS share orthostatic intolerance and fatigue. Orexin to autonomic to orthostatic intolerance applies directly to ME/CFS, supporting the view that orexin pathway dysfunction contributes beyond sleep disturbance alone.
Certainty Assessment:
- Quality: Medium (Biomedicines/MDPI; open access)
- Certainty: 0.45 (mechanistically plausible; human data absent)
- Limitations: Narrative review; no original data; many claims extrapolated from animal studies
8 Heinicke et al. 2025 — Plasma Orexin-A in Severe COVID-19 ICU Patients
Full Citation:: Heinicke U, Talbot SR, Thanasis F, Adam EH, von Knethen A, Steinbicker AU, Zinn S, Zacharowski K, Flinspach AN. Systemic role of orexin A, substance P, bradykinin, and DABK in severe COVID-19 and 2.5-yr follow-ups: an observational study. BJA Open. 2025;14:100415. DOI:: 10.1016/j.bjao.2025.100415 PMID:: 40529720 Study Design:: Single-centre observational cohort Sample Size:: 78 ICU COVID-19 patients; 14 survivors at 2.5-yr follow-up; 14 healthy controls; 423 ELISA measurements
Key Findings: Plasma orexin-A concentrations correlate with ICU survival (Cohen’s \(d\)=0.4) and inversely with length of stay (\(r\)=–0.26, \(p\)=0.02) in severe COVID-19. Bradykinin and substance P were reduced acutely; DABK elevated. At 2.5-year follow-up, substance P remained elevated, potentially contributing to Long COVID neuropsychological symptoms. Bradykinin–substance P–orexin axis dynamics associated with disease severity and prognosis.
Relevance to ME/CFS: First observational study measuring plasma orexin-A in a post-COVID follow-up cohort. Long-term neuropeptide perturbations consistent with ME/CFS post-infectious orexin hypothesis. Bradykinin axis involvement an additional shared pathway with ME/CFS.
Certainty Assessment:
- Quality: Medium (BJA Open, peer-reviewed; prospective cohort)
- Sample: n=78 acute, n=14 follow-up (modest)
- Certainty: 0.50 (direct measurement; confounded by sedation and ICU medications)
- Limitations: Single-centre; ICU population not directly analogous to ME/CFS; no ME/CFS controls
9 Mitochondrial and Metabolic Support: Amino Acids
Rationale for Multi-Amino Acid Approach
ME/CFS is characterized by documented metabolic and mitochondrial dysfunction, including deficiencies in specific amino acids and TCA/urea cycle intermediates. Evidence supports a comprehensive multi-amino acid approach rather than single-agent supplementation.
Myhill et al. 2009 — Mitochondrial Dysfunction Biomarker
Full Citation:: Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med. 2009;2(1):1–16. PMID:: 19436827 PMCID:: PMC2680051 Study Design:: Case-control with ATP profile testing Sample Size:: n=71 ME/CFS patients, 53 controls
Key Findings: Using the ATP Profile test (measuring ATP levels, ADP-to-ATP conversion efficiency, and mitochondrial membrane integrity), 98.6% of ME/CFS patients showed measurable mitochondrial dysfunction. The degree of dysfunction correlated with symptom severity (\(p\)<0.001). This established objective biomarker evidence for the metabolic hypothesis of ME/CFS.
Yamano et al. 2016 — TCA and Urea Cycle Deficiencies
Full Citation:: Yamano E, Sugimoto M, Hirayama A, et al. Index markers of chronic fatigue syndrome with dysfunction of TCA and urea cycles. Scientific Reports. 2016;6:34990. DOI:: 10.1038/srep34990 PMID:: 27725700 PMCID:: PMC5057083 Study Design:: Comprehensive metabolomics (plasma) Sample Size:: n=133 ME/CFS patients, 66 healthy controls
Key Findings: Rigorous metabolomic analysis revealed significantly decreased plasma concentrations of:
- Citrulline (urea cycle intermediate, NO precursor)
- Malate (TCA cycle intermediate, ATP production)
- Isocitrate, citrate (TCA cycle)
Diagnostic markers: pyruvate/isocitrate ratio and ornithine/citrulline ratio distinguished ME/CFS from controls with high sensitivity/specificity. Published in Nature Scientific Reports—high methodological quality.
Relevance: Provides direct biochemical evidence for TCA cycle and urea cycle dysfunction in ME/CFS, supporting supplementation with citrulline-malate to restore these metabolic pathways.
Shungu et al. 2012 — Brain Glutathione Deficiency
Full Citation:: Shungu DC, Weiduschat N, Murrough JW, et al. Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR in Biomedicine. 2012;25(9):1073–1087. DOI:: 10.1002/nbm.2772 PMID:: 22281935 PMCID:: PMC3896083 Study Design:: MRS brain imaging with pilot intervention Sample Size:: n=15 ME/CFS patients, 15 controls
Key Findings: Magnetic resonance spectroscopy (MRS) demonstrated significantly reduced cortical glutathione in ME/CFS compared to controls. Glutathione levels correlated strongly with physical functioning (\(\rho\) = 0.506) and energy (\(\rho\) = 0.606), both \(p\)<0.001. Pilot intervention: 1800 mg/day N-acetylcysteine (NAC) for 4 weeks normalized brain glutathione, ventricular lactate, AND clinical symptoms.
Relevance: Provides direct brain imaging evidence for oxidative stress and glutathione deficiency in ME/CFS, with pilot data supporting NAC supplementation. An NINDS trial is ongoing testing 900 mg vs 3600 mg/day NAC.
Myhill et al. 2012 — Clinical Audit of Comprehensive Protocol
Full Citation:: Myhill S, Booth NE, McLaren-Howard J. Targeting mitochondrial dysfunction in the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) – a clinical audit. Int J Clin Exp Med. 2012;6(1):1–15. PMID:: 23289015 PMCID:: PMC3523104 Study Design:: Clinical audit with biomarker monitoring Sample Size:: n=30 compliant patients (of 67 total)
Key Findings: Comprehensive mitochondrial support protocol including amino acids (L-carnitine), CoQ10, magnesium, B vitamins, and D-ribose produced 4-fold improvement in ATP Profile scores in compliant patients. Non-compliant patients showed no improvement, supporting causality. Protocol also required dietary modification (low-carb, whole foods), sleep optimization, and pacing.
Certainty Assessment:
- Quality: Medium (clinical audit, not RCT, but with objective biomarkers)
- Replication: Consistent with metabolomic studies (Yamano, Shungu)
- Limitations: Single clinic, self-selected adherent population, no placebo control
- Implication: Comprehensive approach validated; isolated component efficacy unknown
Ogawa et al. 1998 — L-Arginine Alone Insufficient
Full Citation:: Ogawa R, Toyama S, Yamamoto Y. L-arginine fails to enhance natural killer activity in chronic fatigue syndrome. International Journal of Molecular Medicine. 1998;2(6):735–739. DOI:: 10.3892/ijmm.2.6.735 PMID:: 9850744 Study Design:: In vitro NK cell stimulation Sample Size:: n=20 (10 CFS, 10 controls)
Key Findings: L-arginine enhanced NK cell activity in healthy controls but failed to enhance NK activity in CFS patients, despite normal NO synthase gene expression. This indicates pathway dysfunction rather than substrate deficiency—supplementation alone insufficient without addressing downstream issues.
Relevance: Critical finding: Single amino acid supplementation (arginine alone) does not work in ME/CFS. Multiple deficiencies require multiple interventions. L-citrulline (bypasses hepatic first-pass, more effectively raises arginine levels) combined with cofactors may be more effective.
Evidence-Based Amino Acid Protocol
Based on the above literature, a comprehensive approach includes:
Core Components (High Certainty for Deficiency):
- N-Acetylcysteine (NAC): 1800 mg/day (600 mg TID) — restores glutathione, pilot efficacy data
- L-Citrulline-Malate: 6–8 g/day — addresses documented TCA/urea cycle deficiencies
- L-Carnitine: 1000–1500 mg/day — mitochondrial fatty acid transport (contraindicated in hypothyroidism)
Essential Cofactors:
- Magnesium: 400–600 mg/day (glycinate or malate forms)
- Coenzyme Q10: 100–300 mg/day (ubiquinol form preferred)
- B-complex vitamins (especially B3, B12)
- D-ribose: 5–15 g/day (ATP precursor)
Targeted Additions:
- L-Lysine: 1000–2000 mg/day during viral reactivation only (competes with arginine for viral replication)
- L-Arginine: Only in combination with citrulline (not as monotherapy)
Safety Considerations:
- L-Carnitine contraindicated in hypothyroidism/Hashimoto’s
- L-Lysine: caution with cardiovascular disease, not for indefinite use
- NAC: GI effects common initially; FDA-approved drug with established safety
- Start low, go slow: test individual tolerance before full dosing
Certainty Summary:
- Metabolic deficiencies: HIGH certainty (rigorous metabolomics, MRS imaging)
- Single amino acid efficacy: LOW (arginine alone failed)
- Comprehensive protocol efficacy: MEDIUM (clinical audit with biomarkers, needs RCT)
- NAC specifically: MEDIUM-HIGH (pilot data positive, RCT ongoing)
Research Gaps:
- No RCTs of individual amino acids in ME/CFS
- Factorial designs needed to determine essential components
- Optimal dosing and duration unclear
- Biomarker-guided personalization not validated
11 Palmitoylethanolamide (PEA)
Overview
Palmitoylethanolamide (PEA) is an endogenous fatty acid amide with anti-inflammatory, analgesic, and mast cell-stabilizing properties. It acts primarily through PPAR-\(\alpha\) activation and has emerging evidence for ME/CFS and related conditions.
Mechanism of Action
- PPAR-\(\alpha\) agonist: Activates peroxisome proliferator-activated receptor alpha, reducing inflammatory gene expression
- Mast cell stabilization: Reduces mast cell degranulation and histamine release
- Endocannabinoid modulation: Enhances anandamide signaling without direct CB receptor activation
- Neuroinflammation: Reduces glial activation and neuroinflammatory markers
Clinical Evidence
Patient-Reported Outcomes (PNAS 2025):: A study of >3,900 ME/CFS and Long COVID patients found PEA had a 41.5% positive response rate in patient-reported outcomes. Pain Efficacy:: Spanish 2025 review confirms PEA effective for nociceptive, neuropathic, and nociplastic pain, with effects typically appearing after 4–6 weeks. Clinical Experience:: At IIMEC 2024, Dr. Jesper Mehlsen reported approximately 600–700 patients (of >1,000) in his clinic taking PEA, with some reporting “I can’t live without PEA.”
Dosing:
- Standard dose: 600–1200 mg/day
- Higher doses (1200 mg/day) more effective for chronic pain
- Ultramicronized forms (um-PEA) have better bioavailability, allowing lower doses
- Effects typically require 4–6 weeks to manifest
Certainty Assessment:
- Quality: Medium (patient-reported outcomes, clinical experience, mechanistic studies)
- ME/CFS-specific trials: None published
- Safety: Excellent (endogenous compound, well-tolerated)
- Rationale: Strong mechanistic basis for MCAS/inflammation/pain management
- Clinical use: Reasonable as adjunct for pain, inflammation, or MCAS symptoms
12 D-Ribose
Teitelbaum et al. 2006 — Pilot Study
Full Citation:: Teitelbaum JE, Johnson C, St Cyr J. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. J Altern Complement Med. 2006;12(9):857–862. DOI:: 10.1089/acm.2006.12.857 PMID:: 17109576 Study Design:: Open-label pilot study Sample Size:: n=41 (FMS and/or CFS patients) Intervention:: 5 g D-ribose three times daily
Key Findings: D-ribose resulted in significant improvement across all five visual analog scale (VAS) categories: energy, sleep, mental clarity, pain intensity, and well-being. Additionally:
- 66% of patients experienced significant improvement
- Average energy increase: 45%
- Average well-being improvement: 30%
- Well-tolerated with minimal side effects
Larger Multicenter Study: A subsequent multicenter study enrolled 257 patients across 53 US clinics, confirming the pilot findings with similar improvements in fatigue, sleep, cognitive function, and overall well-being.
Mechanism: D-ribose is a pentose sugar essential for ATP synthesis. In ME/CFS:
- ATP recycling is impaired (slow ADP → ATP conversion)
- D-ribose levels decline during low-oxygen states
- Supplementation provides substrate for de novo ATP synthesis
- Works synergistically with other mitochondrial supports (CoQ10, carnitine, magnesium)
Dosing: 5 g three times daily (15 g/day total). Effects may be seen within days. Continue at this dose while improvement continues, then consider maintenance dosing. Best combined with comprehensive mitochondrial support protocol.
Certainty Assessment:
- Quality: Low-Medium (open-label studies only, no RCTs)
- Sample: Adequate (257 in multicenter study)
- Replication: Consistent across two studies
- Mechanistic support: Strong (ATP metabolism well-understood)
- Limitations: No placebo control, potential for placebo effect
- Clinical use: Reasonable as part of mitochondrial support; safe, inexpensive
13 Low-Dose Aripiprazole (LDA)
Crosby et al. 2021 — Stanford Retrospective Study
Full Citation:: Crosby LD, Kalanidhi S, Engel A, et al. Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole. J Transl Med. 2021;19(1):50. DOI:: 10.1186/s12967-021-02721-9 PMID:: 33536023 PMCID:: PMC7860172 Study Design:: Retrospective chart review Sample Size:: n=101 ME/CFS patients Setting:: Stanford University
Key Findings: Of 101 patients taking low-dose aripiprazole (0.2–2.0 mg/day, mean 1.1 mg/day):
- 74% (75/101) experienced improvement in one or more categories
- Fatigue score improved by \(-\) 2.89 units (\(p\) < 0.001)
- Brain fog improved by \(-\) 2.33 units (\(p\) < 0.001)
- Unrefreshing sleep improved by \(-\) 2.05 units (\(p\) < 0.001)
- PEM frequency reduced from every 4.2 days to every 8.3 days
- 18 patients reported complete resolution of PEM
- 6 patients able to return to work
- 12% no response; 14% discontinued due to side effects
Mechanism: Aripiprazole is a D2 receptor partial agonist (intrinsic activity ~25% of full agonism) at all doses — the molecule’s mechanism does not change with dose. Because it binds with high affinity and clamps receptor output toward this fixed intermediate set point, its net effect is tone-dependent: where ambient dopamine is high (e.g., mesolimbic overactivity in psychosis) it displaces dopamine and reduces signaling, appearing antagonist-like; where ambient dopamine is low (the proposed hypodopaminergic state in ME/CFS) it holds signaling up, appearing agonist-like. Hence the “dopamine stabilizer” label. The relevance of low doses (0.2–2 mg) is a matter of fractional receptor occupancy and possible preferential engagement of non-D2 / microglial targets, not a switch in intrinsic activity; whether this constitutes a therapeutically distinct regime versus simply a low, better-tolerated dose has not been established. Proposed mechanisms for ME/CFS benefit:
- D2 receptor partial agonism may reduce neuroinflammation
- Modulation of microglial activation
- Enhanced dopaminergic tone in reward/motivation circuits
Dosing: Start at 0.25 mg/day; titrate based on response and tolerability up to maximum 2 mg/day. Compounding pharmacies needed for doses below 1 mg (standard tablets are 2 mg+).
Certainty Assessment:
- Quality: Low-Medium (retrospective, no control group)
- Sample: Adequate (n=101)
- Replication: None (single study)
- Limitations: Retrospective design, no placebo control, selection bias, atypical antipsychotic class
- Safety concerns: Metabolic effects (weight gain, glucose dysregulation) even at low doses; requires monitoring
- Clinical use: Consider for treatment-refractory patients with informed consent about uncertain evidence and need for metabolic monitoring
14 Autonomic Dysfunction: Ivabradine and Pyridostigmine
Ivabradine for POTS
Drug Class:: Selective If (funny channel) inhibitor FDA Approval:: Heart failure (off-label for POTS) Mechanism:: Reduces heart rate without affecting blood pressure (unlike beta-blockers)
Recent Evidence (2025): A 2025 study in the Journal of Cardiovascular Pharmacology found ivabradine treatment significantly reduced:
- Change in heart rate with standing (\(\Delta\)HR): from 40 (30–70) to 15 (8–19) bpm
- Malmö symptom score: from 86 to 39 (\(p\) = 0.005)
- Strong correlation between \(\Delta\)HR reduction and symptom improvement (\(R\) = +0.828)
Systematic Review (2025): A systematic review in Clinical Autonomic Research examined POTS treatment with special focus on ME/CFS comorbidity. Ivabradine and midodrine demonstrated the highest rates of symptomatic improvement among medications studied. 67–100% of patients showed symptomatic benefit across studies.
Certainty Assessment:
- Quality: Low-Medium (small studies, mostly observational)
- Efficacy: Consistent heart rate reduction and symptom improvement
- Advantage over beta-blockers: No blood pressure reduction, less fatigue
- ME/CFS applicability: High (30–40% of ME/CFS patients have POTS)
- Clinical use: First-line consideration for ME/CFS patients with documented POTS
Pyridostigmine (Mestinon)
Drug Class:: Acetylcholinesterase inhibitor FDA Approval:: Myasthenia gravis (off-label for POTS/ME/CFS) Mechanism:: Increases acetylcholine, enhances parasympathetic tone, improves venous return
Systrom et al. 2022 — Randomized Controlled Trial
Full Citation:: Joseph P, Arevalo C, Engel AG, et al. Neurovascular Dysregulation and Acute Exercise Intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Placebo-Controlled Trial of Pyridostigmine. Chest. 2022;162(5):1116–1126. DOI:: 10.1016/j.chest.2022.04.146 PMID:: 35526605 Study Design:: Single-center, randomized, double-blind, placebo-controlled Sample Size:: n=45 ME/CFS patients
Key Findings: Patients received 60 mg pyridostigmine or placebo between two invasive cardiopulmonary exercise tests (iCPET):
- Peak VO2 increased after pyridostigmine but decreased after placebo
- Pyridostigmine improved cardiac output and right ventricular filling pressures
- Worsening after placebo may signal onset of PEM
- Supports hypothesis that treatable neurovascular dysregulation underlies acute exercise intolerance
Clinical Experience: Grubb reported 43% of 203 POTS patients (51% of those tolerating the drug) experienced benefit. Most commonly improved: fatigue (55%), palpitations (60%), presyncope (60%), syncope (48%).
Dosing: Start 30 mg once daily; increase to 30 mg 2–3 times daily as tolerated. Common side effects include GI upset, muscle cramps, increased salivation. Caution in asthmatics (increases bronchial secretions).
Certainty Assessment:
- Quality: Medium-High (RCT with objective outcomes)
- Sample: Adequate (n=45)
- Mechanistic: Objective improvement in cardiac output and oxygen uptake
- Clinical applicability: High for patients with exercise intolerance and preload failure
- Limitations: Single-dose acute study; long-term efficacy not established in RCT
15 Graded Exercise Therapy (Negative Evidence)
Full Citation:: Geraghty K, Hann M, Kurtev S. The Updated NICE Guidance Exposed the Serious Flaws in CBT and Graded Exercise Therapy Trials for ME/CFS. Healthcare. 2022;10(5):898. DOI:: 10.3390/healthcare10050898 PMCID:: PMC9141828 Key Findings:: Methodological flaws and biases in trials; patient surveys show harm from GET.
Full Citation:: Vink M, Vink-Niese A. The PACE Trial’s GET Manual for Therapists Exposes the Fixed Incremental Nature of Graded Exercise Therapy for ME/CFS. Life. 2025;15(4):584. DOI:: 10.3390/life15040584
Full Citation:: Vink M, Vink-Niese A. Graded exercise therapy does not restore the ability to work in ME/CFS – Rethinking of a Cochrane review. Work. 2020;66(2):283–308. DOI:: 10.3233/WOR-203174 PMID:: 32568149
16 Neuromodulation: Transcutaneous Vagus Nerve Stimulation
Natelson et al. 2022 — tVNS for Long COVID-ME/CFS (Pilot)
Full Citation:: Natelson BH, Vu T, Mao X, Soto O, Stegner A, Yamamoto Y, Scherl E, Togo F, Lange G. Transcutaneous Vagus Nerve Stimulation in the Treatment of Long COVID-Chronic Fatigue Syndrome. medRxiv. 2022. doi:10.1101/2022.11.08.22281807 DOI:: 10.1101/2022.11.08.22281807 Publication Status:: Preprint (not peer-reviewed) Study Design:: Open-label pilot study (no sham control) Sample Size:: n=14 completers (16 enrolled) Population:: Long COVID patients meeting 1994 CFS case definition criteria Intervention:: Parasym tVNS device, left tragus placement, 35+ minutes daily for 6 weeks
Key Findings: 8 of 14 patients (57%) met success criteria (improvement on ≥2 of 4 outcome measures: SF-36 physical function ≥14% improvement, symptom severity VAS reduction ≥2 points, loss of “fatigue case” status on Chalder scale, or Patient Global Impression of Change +2/+3). No adverse effects reported during the 6-week trial. The 57% response rate exceeds typical ME/CFS placebo response ( 24%) but causality cannot be established without sham control.
Relevance: First pilot study of tVNS specifically for ME/CFS (Long COVID subset). Suggests potential benefit through vagal nerve modulation of autonomic and immune function. The intervention is low-cost, non-invasive, home-based, and well-tolerated, making it suitable for severe ME/CFS patients. However, the open-label design and small sample size limit interpretability.
Certainty Assessment:
- Quality: Low to Medium (open-label pilot, small n, no sham control, preprint status)
- Sample: n=14 (very small)
- Replication: None (single study, no independent replication)
- Conflicts: Device donated by manufacturer; study funded by patient donations
- Limitations: Cannot rule out placebo effect; no mechanistic biomarkers measured; patient-adjusted intensity (no standardized parameters); no follow-up data on durability
- Clinical Recommendation: Preliminary evidence only; requires sham-controlled RCT validation before clinical adoption
Yu et al. 2022 — tVNS for POTS (Provides Mechanistic Context)
Full Citation:: Yu L, Huang B, Po SS, et al. Transdermal auricular vagus stimulation for the treatment of postural tachycardia syndrome. Autonomic Neuroscience: Basic and Clinical. 2022;243:103021. DOI:: 10.1016/j.autneu.2021.103021 PMID:: 35183906 Study Type:: Narrative review synthesizing multiple tVNS studies in POTS Relevance to ME/CFS:: POTS affects 30–40% of ME/CFS patients; shared autonomic dysfunction mechanisms
Key Findings: Acute effects (n=14, randomized crossover): Significant improvement in tilt test tolerance time (+5.3\(\pm\) 2.6 min, \(p\)=0.0156) and reduced orthostatic symptom scores. Chronic effects (n=9, open-label, 2 weeks): Significant reductions in COMPASS-31 total score and orthostatic intolerance domain (both \(p\)<0.05). Mechanisms: (1) Autonomic rebalancing (improved heart rate variability), (2) Reduction of \(\beta\) 1-adrenergic receptor and \(\alpha\) 1-AR autoantibodies (significant in active vs sham), (3) Decreased serum TNF-\(\alpha\) levels, (4) Activation of cholinergic anti-inflammatory pathway via \(\alpha\) 7 nicotinic acetylcholine receptors on macrophages. Responder phenotype: Patients with low baseline vagal modulation (high-frequency HRV <200 ms2) showed greatest improvement.
Relevance: Provides mechanistic rationale for tVNS in ME/CFS through POTS studies. Both autonomic rebalancing and anti-inflammatory effects are relevant to ME/CFS pathophysiology. Adrenergic receptor autoantibodies and elevated TNF-\(\alpha\) are also reported in ME/CFS subgroups, suggesting therapeutic overlap. However, efficacy is established specifically for POTS; extrapolation to ME/CFS without POTS requires validation.
Protocol Parameters: Cymba conchae stimulation, 25–50 Hz frequency, 200–300 microsecond pulse width, subsensory to tolerated current (typically <2 mA), 30-second on/off duty cycle, 4 hours daily for chronic protocols. Baseline HRV testing may identify likely responders.
Certainty Assessment:
- Quality (for POTS): Medium (includes randomized crossover but chronic study lacks sham control)
- Sample: Small (n=9–14)
- Replication: Multiple studies but same research group
- Limitations: Short duration (2 weeks chronic); small samples; single research group; POTS-specific population
- ME/CFS Applicability: Medium (shared pathophysiology, high POTS comorbidity) to Low (no direct ME/CFS validation beyond Natelson pilot)
- Clinical Recommendation: Evidence-based for ME/CFS patients with documented POTS; investigational for broader ME/CFS application
Integration Notes: tVNS represents a potential non-pharmacological, home-based intervention for autonomic and immune modulation in ME/CFS. The dual mechanisms (vagal tone enhancement + cholinergic anti-inflammatory pathway) address multiple pathophysiological features. Safety profile is favorable with minimal adverse effects across studies. However, current evidence is preliminary: the ME/CFS pilot lacks sham control, and POTS studies have small samples and short durations. Baseline autonomic testing (HRV) may enable precision medicine approach by identifying likely responders. Larger sham-controlled RCTs in ME/CFS populations are needed before clinical adoption beyond POTS subgroup.
Bu et al. 2026 — VNS Mechanisms: Fibre Selectivity and Anatomical Architecture
Full Citation:: Bu Y, Liang A, Hoffman BU, Schiehser DM, Case O, Simmons A, Klaming R, Gottfried-Blackmore A, Mittal RK, Puleo C, Lim H, Lerman I. A Review of Vagus Nerve Stimulation for Disease: Comprehensive Theory and Evidence for Mechanisms of Action. Comprehensive Physiology. 2026;16(2):e70109. DOI:: 10.1002/cph4.70109 PMID:: 41781173 Published:: April 2026 Study Design:: Comprehensive narrative review with anatomical data Key Findings::
- Cervical vagus cross-section (Figure 2A) reveals multi-fascicle architecture: the nerve is not a uniform cable but contains heterogeneous bundles with distinct fibre populations — large myelinated A-fibres, smaller myelinated B-fibres, and unmyelinated C-fibres
- Fibre recruitment follows biophysical activation thresholds: A-fibres recruited first at lowest intensities (explaining voice hoarseness as the most common cervical VNS side effect — laryngeal efferent A-fibres engage before autonomic fibres), then B-fibres (preganglionic autonomic efferents: heart rate, bronchomotor tone, gut motility), then C-fibres (visceral/nociceptive/inflammatory signals; highest threshold)
- C-fibres are numerically dominant and carry the inflammatory signals most relevant to ME/CFS pathophysiology, but require higher effective activation thresholds — robust C-fibre recruitment co-occurs with full A- and B-fibre engagement unless deliberate fibre-selectivity strategies are used
- Electrode geometry, pulse width, frequency, duty cycle, and waveform shape all determine which fibre classes are actually recruited in a given protocol
- Critical interpretive principle: when a study reports "VNS" effects on inflammation, fatigue, or cardiac function, the key question is not nominal dose but which fibre classes were plausibly engaged under those specific anatomical and parameter conditionsRelevance to ME/CFS:: Provides the mechanistic framework for interpreting all VNS literature in ME/CFS. The anti-inflammatory C-fibre pathway is not simply “dialled up” by increasing stimulation intensity — parameter specificity determines which pathways are engaged. Studies reporting VNS effects on inflammation in ME/CFS should be evaluated against their specific electrode placement, waveform, and parameters; cross-study comparison of aggregate “VNS effects” is difficult to interpret without this specification. Essential context for evaluating Natelson 2022 (tVNS pilot) and Yu 2022 (POTS data) in light of whether the anti-inflammatory C-fibre pathway was plausibly activated under the parameters used. Certainty Assessment::
- *Quality:* High (Comprehensive Physiology; peer-reviewed; anatomical data with imaging evidence)
- *Study type:* Comprehensive review with primary anatomical data (cross-sectional imaging)
- *Limitations:* Review methodology; anatomical data from non-ME/CFS specimens; parameter thresholds are from general peripheral nerve biophysics, not ME/CFS-specific validation
- *Convergence:* Consistent with established peripheral nerve biophysics; provides anatomical evidence that was previously described theoretically17 Pacing and Energy Management
Full Citation:: Goudsmit EM, Nijs J, Jason LA, Wallman KE. A scoping review of “Pacing” for management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): lessons learned for the long COVID pandemic. Journal of Translational Medicine. 2023;21:738. DOI:: 10.1186/s12967-023-04586-6 PMCID:: PMC10576275
DOI:: 10.1080/21641846.2012.733602 PMCID:: PMC3596172
18 Patient-Reported Treatment Outcomes
Full Citation:: Davis HE, McCorkell L, Vogel JM, et al. Patient-reported treatment outcomes in ME/CFS and long COVID. Proceedings of the National Academy of Sciences. 2025;122(26):e2426874122. DOI:: 10.1073/pnas.2426874122 PMCID:: PMC12280984 Sample:: \(>\) 3,900 patients Key Findings:: Treatment responses highly correlated (\(R^2\)=0.68) between ME/CFS and Long COVID.